SCHEMBL5422148

SCHEMBL5422148

CCOC(=O)c1cc(C2CC2)c2c(C)c(-c3cccnc3)ccn2c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 1/20 0.43
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
KDM4E B2RXH2 5/20 0.41
ALDH1A1 P00352 4/20 0.41
HPGD P15428 4/20 0.41
GAA P10253 3/20 0.41
GLA P06280 2/20 0.41
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 2/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
MMP2 P08253 1/20 0.39
MMP13 P45452 1/20 0.39
MMP14 P50281 1/20 0.39
GABRA1 P14867 2/20 0.37
GABRA5 P31644 1/20 0.37
POLB P06746 1/20 0.37
CDK5 Q00535 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1290033 0.91 GABRA1 (0.46) KDM4EALDH1A1HPGDTSHRHSD17B10
SCHEMBL1290246 0.88 TOP2A (0.39) KDM4EALDH1A1GAAMKNK2
SCHEMBL1290222 0.85 KDM4E (0.43) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL4966503 0.85 ALDH1A1 (0.44) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL5428842 0.84 ALDH1A1 (0.41) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL1290318 0.84 KDM4E (0.41) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL1290014 0.84 KDM4E (0.43) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL5418075 0.84 KDM4E (0.41) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL1290164 0.84 KDM4E (0.41) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL5424777 0.84 KDM4E (0.42) RAB9AKDM4EALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223773-B2 4-oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SALO PHARMACEUTICAL CO., LTD. (JP) 2007-05-29 US disclosed
US-20040229903-A1 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SATO PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
EP-1437354-A1 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETON AS PARTIAL STRUCTURE Sato Pharmaceutical Co. Ltd. (JP) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229903-A1 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SDHA, IL4I1, BLVRB DCTPP1 3540/4885RAB9A 3181/4885NPC1 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.